Status:
RECRUITING
IV Ketamine Vs. in Esketamine for MDD TRD
Lead Sponsor:
Gustavo Vazquez
Collaborating Sponsors:
Centre for Addiction and Mental Health
Envision Mind Care
Conditions:
Treatment Resistant Depression
Eligibility:
All Genders
18-75 years
Brief Summary
The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suici...
Detailed Description
This is a multi-center observational prospective cohort study in Providence Care Hospital in Kingston, ON; Envision Mind Care in Edmonton, AB; Center for Addiction and Mental Health in Toronto, ON; th...
Eligibility Criteria
Inclusion
- Adult outpatients (18-75 years old) with unipolar depression experiencing major depressive episodes as determined by the DSM5 and characterized as MDD-TRD (diagnosed with major depressive disorder as outlined by the DSM5) and experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode
Exclusion
- Individuals with psychosis, main diagnosis of personality disorder, uncontrolled hypertension, substance abuse, currently pregnant or breastfeeding, or who had a previous negative reaction to ketamine or esketamine, were ineligible to receive IV ketamine or IN esketamine.
Key Trial Info
Start Date :
March 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 20 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06488586
Start Date
March 20 2023
End Date
October 20 2026
Last Update
July 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence Care Hospital
Kingston, Ontario, Canada, K7L4X3